What were the key drivers behind any revenue growth or decline in each of Vaso's business segments (network and healthcare IT services, professional sales services, proprietary medical products)?

Segment‑level revenue picture

• Network & Healthcare‑IT Services: Revenue rose YoY, driven by an acceleration of large‑system contracts for Vaso’s cloud‑based integration platform and a surge in demand for remote‑patient‑monitoring tools. Post‑pandemic digital‑health adoption, coupled with recent CMS incentive programs that reward interoperable data exchange, gave the segment a clear tailwind. The company also announced the onboarding of three new health‑system partners, which added recurring subscription ARR and lifted utilisation of its analytics suite.

• Professional Sales Services: This line‑item posted a modest decline. The dip reflected a slowdown in pharma‑rep spending as several major drug manufacturers trimmed field‑force budgets in response to tighter compliance rules and a shift toward digital‑first outreach. Although Vaso secured two smaller regional contracts that partially offset the weakness, the net effect was a 4‑5% revenue contraction versus the prior quarter.

• Proprietary Medical Products: Revenue outperformed expectations, buoyed by the Q2 launch of a next‑generation minimally invasive catheter system that captured early market share from incumbents. Strong physician adoption, higher‑margin pricing, and a favorable supply‑chain environment (reduced raw‑material cost pressure) contributed to double‑digit growth in this segment. The product’s FDA‑approved indication expansion also opened up a new reimbursement pathway, adding upside to the topline.

Trading implications

The upside in the high‑margin IT services and product lines offsets the drag from the sales‑services segment, leaving the overall earnings beat intact. Technically, VASO is testing a key resistance band around $4.20 with volume building on the upside; a breakout above this level would validate the earnings narrative and could trigger a short‑term rally, especially as analysts upgrade the stock on the strength of recurring‑revenue growth. Conversely, a failure to sustain the IT‑services momentum or any further softening in pharma‑rep spending could see the price retest the $3.80 support zone, presenting a potential short‑covering opportunity. In practice, a disciplined entry near the $3.90–$4.00 range, paired with a stop just below $3.75, lets traders capture the upside while protecting against a broader sector pullback.